Traditional Chinese medicine composition for treating atherosclerosis complicated with hyperhomocysteinemia as well as preparation method and application of traditional Chinese medicine composition
The treatment side effects and limited efficacy of atherosclerosis and hyperhomocysteinemia are solved by preparing traditional Chinese medicine compositions, including cooked Rehmannia, Cistanche, Raw Astragalus, Salvia miltiorrhiza and Safflower. The problem has achieved a significant reduction in homocysteine and blood lipid levels, improving the quality of life of patients.
Patent Information
- Application Number
- CN202411062285.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-05
AI Technical Summary
The prior art has problems with greater side effects or limited efficacy in the treatment of atherosclerosis and hyperhomocysteinemia, especially the problems of liver and kidney damage treated by Western medicine and the difficulty of long-term use of patients. Traditional Chinese medicine treatment is Safety and efficacy need to be improved.
Provided is a traditional Chinese medicine composition, including cooked Rehmannia, Cistanche, raw Astragalus, Salvia miltiorrhiza and safflower. It is prepared into a mixture or granule by decoction, filtrate concentration, ethanol recovery and flocculation precipitation methods, tonify kidneys and fill sperm, promote blood circulation and unblock meridians. , reduce homocysteine levels and blood lipid levels.
It significantly reduces the occurrence of atherosclerosis-related complications, improves patient symptoms, reduces the incidence of atherosclerosis-related complications, and shows superiority in safety and side effects.
Smart Images

Figure BDA0004978297110000111 
Figure BDA0004978297110000112 
Figure BDA0004978297110000121
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia; the invention also relates to a preparation method and application of the traditional Chinese medicine composition. Background Art
[0002] 1. The current status of atherosclerosis in the health field in my country
[0003] At present, the leading cause of death among community residents in my country is cardiovascular and cerebrovascular diseases, which account for more than 40% of the total death rate, higher than tumors and other diseases. In particular, the mortality rate of cardiovascular diseases in rural areas has continued to be higher than that in cities in recent years. Data released by the American College of Cardiology and the European Society of Cardiology also show that cardiovascular disease is the leading cause of death, among which the burden of coronary heart disease ranks first and stroke ranks second. The economic losses caused by cardiovascular diseases reach 329.7 billion US dollars each year. Atherosclerosis (AS) is the most common pathological basis of cardiovascular and cerebrovascular diseases, and acute cardiovascular and cerebrovascular events are often caused by plaque rupture in the later stage. Therefore, how to effectively limit the progression of atherosclerosis and prevent the occurrence of serious cardiovascular and cerebrovascular events is of great significance.
[0004] 2. Atherosclerosis and hyperhomocysteinemia
[0005] Plasma homocysteine (Hcy) is a sulfur-containing amino acid and an important metabolite of methionine and cysteine. When methionine and cysteine metabolism is impaired, the level of homocysteine (Hcy) in the blood increases. Plasma homocysteine levels above 10μmol / L are called hyperhomocysteinemia (HHcy) or elevated plasma Hcy levels. Studies have shown that elevated plasma Hcy levels are an independent risk factor for atherosclerosis. When plasma Hcy levels increase by 5μmol / L, the risk of coronary heart disease increases by 20%. On the contrary, if Hcy levels decrease by 3μmol / L, the risk of coronary heart disease decreases by 11%. HHcy may cause atherosclerosis by acting on vascular endothelial cells, causing functional damage; and promoting the proliferation of vascular smooth muscle cells, platelet adhesion and aggregation, oxidative modification of low-density lipoproteins, and increased arterial stiffness during the process of atherosclerosis.
[0006] Increased homocysteine (Hcy) concentration in the blood can promote the degradation of elastic fibers and the synthesis of collagen fibers, which can reduce the elastin / collagen ratio in the middle layer of blood vessels, reduce the distensibility of large arteries, and increase stiffness. Studies have found that after adjusting for risk factors such as age, mean blood pressure, degree of arterial occlusion, and glomerular filtration rate, Hcy is positively correlated with the pulse wave velocity of the carotid and femoral arteries. In addition, when LP(a) and Hcy increase at the same time, the risk of atherosclerosis increases greatly.
[0007] 3. Overview of Traditional Chinese Medicine in the Treatment of Atherosclerosis Combined with Hyperhomocysteinemia
[0008] Although non-drug treatments for AS and coronary heart disease, including percutaneous coronary intervention and coronary artery bypass grafting, have made great progress, patients are still likely to have cardiovascular events again and face many problems such as in-stent restenosis, stent thrombosis and antiplatelet drug resistance. In terms of Western medicine treatment, statins are currently the main type of drugs used, but they have certain side effects, such as liver and kidney damage or muscle damage, and it is difficult for patients to take them for a long time. Currently, the safest and most effective way to reduce Hcy is to supplement folic acid, which can be combined with or without vitamin B. It is worth noting that the results of some studies suggest that folic acid supplementation can cause prostate cancer.
[0009] Through the combination of four diagnoses and treatment based on syndrome differentiation, Chinese medicine has an advantage that cannot be ignored in the treatment of common cardiovascular and cerebrovascular diseases combined with hyperhomocysteinemia. It has clear efficacy in reducing Hcy, improving blood rheology, stabilizing and regressing atherosclerotic plaques, improving cardiac function and improving the quality of life of patients. Its outstanding features are safety, effectiveness, few side effects, and overall consideration, whole body conditioning, especially suitable for chronic patients. Studies have shown that Chinese medicine has certain advantages in the treatment of hyperhomocysteinemia. Summary of the invention
[0010] In view of the above-mentioned deficiencies in the prior art, according to an embodiment of the present invention, it is hoped to provide a Chinese medicine composition that can treat atherosclerosis, reduce blood homocysteine, and improve the quality of life for patients with atherosclerosis combined with hyperhomocysteinemia, and propose a preparation method and use of the Chinese medicine composition.
[0011] In order to solve the above technical problems, the present invention provides a traditional Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia, which is a medicine prepared from the following raw medicines in parts by weight: 12-15 parts of cooked rehmannia, 9-12 parts of cistanche deserticola, 12-15 parts of raw astragalus, 6-9 parts of cyperus rotundus, 15-30 parts of salvia miltiorrhiza, and 6-9 parts of safflower.
[0012] Preferably, the weight portions of the above-mentioned traditional Chinese medicine composition of the present invention are respectively: 15 parts of Rehmannia glutinosa, 12 parts of Cistanche deserticola, 15 parts of Raw Astragalus, 6 parts of Cyperus rotundus, 15 parts of Salvia miltiorrhiza, and 6 parts of Carthamus tinctorius.
[0013] Preferably, the above-mentioned medicament of the present invention is a mixture.
[0014] Preferably, the above-mentioned medicament of the present invention is a granule.
[0015] The preparation method of the Chinese medicine composition of the present invention is as follows: weigh 6-8 days of raw medicine according to proportion, add 9-11 times and 7-9 times of water respectively, decoct two to three times, combine the filtrate, and concentrate the filtrate to 5 grams of raw medicine per milliliter; add 2-4 times of ethanol to the concentrated solution, the alcohol content is 60%, refrigerate and stand for 22-26 hours, filter, and recover ethanol from the filtrate until there is no alcohol taste; boil the recovered solution, add 2-4 grams of sodium benzoate and 0.23-0.27 grams of ethyl paraben, filter and cool, add water to 480-520 ml, and fill it while it is hot.
[0016] In addition, the above-mentioned Chinese medicine composition of the present invention can also be prepared by the following method: weigh 6-8 days of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush them to 10-40 meshes, and extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times of water to the residues of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius and the remaining raw materials weighed in proportion, decoct them two to three times, combine the filtrate, and concentrate the filtrate to 5 grams of crude drug per milliliter; adopt flocculation precipitation method, stand for 22-26 hours, centrifuge and filter, the centrifugal speed is 4980-5020 rpm, add Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius volatile oil to the filtrate, mix well, add 2-4 grams of sodium benzoate and 0.23-0.27 grams of ethyl paraben, filter and cool, add water to 480-520 ml, and fill it while hot.
[0017] The preparation method of the Chinese medicine composition granules of the present invention is as follows: weigh 6-8 days of raw medicine according to proportion, add 9-11 times and 7-9 times of water respectively, decoct two to three times, combine the filtrate, and concentrate the filtrate to 5 grams of raw medicine per milliliter; add 2-4 times of ethanol to the concentrated solution, the alcohol content is 60%, refrigerate and stand for 22-26 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, concentrate the recovered solution to a relative density of 1.25-1.30, add an appropriate amount of dextrin or starch, wet granulate, dry, make 480-520 grams of granules, and pack them.
[0018] In addition, the above-mentioned Chinese medicine composition granules of the present invention can also be prepared by the following method: weigh 6-8 days of cooked rehmannia, salvia miltiorrhiza, and safflower in proportion, crush them to 10-40 meshes, and extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times of water to the residues of cooked rehmannia, salvia miltiorrhiza, and safflower and the remaining raw materials weighed in proportion, decoct them two to three times, combine the filtrate, and concentrate the filtrate to 5 grams of crude drug per milliliter; adopt the chitosan decoction flocculation precipitation method, let it stand for 22-26 hours, centrifuge and filter, concentrate the mixed solution to a relative density of 1.25-1.30, add an appropriate amount of dextrin or starch and a β-cyclodextrin inclusion complex of the volatile oil of cooked rehmannia, salvia miltiorrhiza, and safflower, wet granulate or one-step granulate, dry at low temperature or in vacuum, prepare granules of 480-520 grams, and pack them.
[0019] The Chinese medicine composition of the present invention is based on the treatment principle of tonifying the kidney and replenishing essence, promoting blood circulation and unblocking collaterals, and is composed of Radix Rehmanniae Preparata, Herba Cistanches, Radix Astragali, Rhizoma Cyperi, Radix Salviae Miltiorrhizae and Safflower as medicines. In this group of medicines, Radix Rehmanniae Preparata and Herba Cistanches can tonify the kidney and replenish essence, Radix Astragali can invigorate the spleen and replenish qi, Rhizoma Cyperi can regulate qi and activate blood circulation, and Radix Salviae Miltiorrhizae and Safflower can activate blood circulation, remove blood stasis and unblock collaterals, and the whole prescription takes both the symptoms and the root causes into consideration.
[0020] Modern pharmacological studies have confirmed that Radix Rehmanniae Preparata and Herba Cistanches have antioxidant effects, improve blood rheology, and have excellent therapeutic effects on neurodegenerative diseases. They can increase coronary flow after reperfusion, reduce coronary resistance, and promote the recovery of myocardial contractility. Radix Astragali and Radix Salviae Miltiorrhizae have the effects of improving myocardial ischemia, dilating blood vessels, resisting thrombosis, reducing blood viscosity, regulating blood lipids, and reducing homocysteine; Radix Cyperi has the effect of regulating blood lipids and oxidative stress disorders; Safflower has the pharmacological effects of inhibiting inflammatory response, inhibiting the proliferation of vascular smooth muscle cells, resisting oxidative stress, resisting platelet aggregation, regulating blood lipids, and reducing homocysteine levels that pose a threat to cardiovascular diseases.
[0021] Clinical trials have shown that the Chinese medicine composition of the present invention has obvious effects of treating atherosclerosis, reducing homocysteine levels and blood lipid levels, improving patient symptoms, and reducing the occurrence of complications related to atherosclerosis. DETAILED DESCRIPTION
[0022] The present invention will be further described below in conjunction with specific embodiments. These embodiments should be understood to be only used to illustrate the present invention and not to limit the scope of protection of the present invention. After reading the content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0023] The Rehmannia glutinosa used in the following embodiments of the present invention is produced in Shanghai and is the tuberous root of Rehmannia glutinosa of the Scrophulariaceae family.
[0024] The origin of the Cistanche deserticola used in the following examples of the present invention is confirmed to be Inner Mongolia, and it is the fleshy stem with scale leaves of the plant Cistanche deserticola YCMa of the Orobanchaceae family.
[0025] The raw astragalus used in the following examples of the present invention is confirmed to be produced in Inner Mongolia, and is the root of Astragalus membranaceus (Fisch.) Bge.var. mongholicus (Bge.) Hsiao, a perennial herb of the Leguminosae family.
[0026] The origin of the Cyperus rotundus used in the following examples of the present invention is confirmed to be Shandong, and it is the dried rhizome of Cyperus rotundus L., a plant of the genus Cyperus in the family Cyperaceae.
[0027] The Danshen used in the following examples of the present invention is confirmed to be produced in Jiangsu, and is the root and rhizome of the perennial herb Salvia miltiorrhiza Bge. of the Lamiaceae family.
[0028] The safflower used in the following examples of the present invention is confirmed to be produced in Yunnan, and is the dried flower of the safflower Carthamustinctorius L. of the Asteraceae family.
[0029] Example 1 (Preparation of a mixture)
[0030] Weigh 6 days' worth of the above medicinal materials in proportion, add 9 times and 7 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of crude drug per milliliter; add 2 times the amount of ethanol to the concentrated solution until the alcohol content reaches about 60%, refrigerate and stand for 22 hours, filter, and recover ethanol from the filtrate until there is no alcohol taste; boil the recovered liquid, add 2 grams of sodium benzoate and 0.23 grams of ethyl paraben (dissolved in water), filter and cool, add water to 480 ml, and fill it while it is hot.
[0031] Example 2 (Preparation of mixture)
[0032] Weigh the 7-day amount of the above medicinal materials in proportion, add 10 times and 8 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of crude drug per milliliter; add 3 times the amount of ethanol to the concentrated solution until the alcohol content reaches about 60%, refrigerate and stand for 24 hours, filter, and recover ethanol from the filtrate until there is no alcohol taste; boil the recovered liquid, add 3 grams of sodium benzoate and 0.25 grams of ethyl paraben (dissolved in water), filter and cool, add water to 500 ml, and fill it while it is hot.
[0033] Example 3 (Preparation of mixture)
[0034] Weigh 8 days' worth of the above medicinal materials in proportion, add 11 times and 9 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of crude drug per milliliter; add 4 times the amount of ethanol to the concentrate until the alcohol content reaches about 60%, refrigerate and stand for 26 hours, filter, and recover ethanol from the filtrate until there is no alcohol taste; boil the recovered liquid, add 4 grams of sodium benzoate and 0.27 grams of ethyl paraben (dissolved in water), filter and cool, add water to 520 ml, and fill while hot.
[0035] Example 4 (Preparation of mixture)
[0036] Weigh 6 days' worth of Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 mesh, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct two to three times, combine the filtrate, and concentrate the filtrate to 5 grams of crude drug per milliliter; adopt flocculation precipitation method, let stand for 22 hours, centrifuge and filter at a centrifugal speed of 4980 rpm, add Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius volatile oil to the filtrate, mix well, add 2 grams of sodium benzoate and 0.23 grams of ethyl paraben, filter and cool, add water to 480 ml, and fill while hot.
[0037] Example 5 (Preparation of a mixture)
[0038] Weigh 7 days' worth of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 mesh, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct for two to three times, combine the filtrate, and concentrate the filtrate to 5 g of crude drug per milliliter; adopt flocculation precipitation method, let stand for 24 hours, centrifuge and filter at a centrifugal speed of 5000 rpm, add volatile oil of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius to the filtrate, mix well, add 3 g of sodium benzoate and 0.25 g of ethylparaben (dissolved in water), filter and cool, add water to 500 ml, and fill while hot.
[0039] Example 6 (Preparation of a mixture)
[0040] Weigh 8 days' worth of Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 mesh, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct two to three times, combine the filtrate, and concentrate the filtrate to 5 g of crude drug per milliliter; adopt flocculation precipitation method, let stand for 26 hours, centrifuge and filter at a centrifugal speed of 5020 rpm, add Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius volatile oil to the filtrate, mix well, add 4 g of sodium benzoate and 0.27 g of ethylparaben, filter and cool, add water to 520 ml, and fill while hot.
[0041] Example 7 (Preparation of granules)
[0042] Weigh 6 days' worth of the raw material medicine in proportion, add 9 times and 7 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of the raw material medicine per milliliter; add 2 times the amount of ethanol to the concentrate, with an alcohol content of 60%, refrigerate and stand for 22 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, concentrate the recovered liquid to a relative density of 1.25-1.30 (room temperature), add an appropriate amount of dextrin or starch, wet granulate, dry, and make 480 grams of granules, which are packaged.
[0043] Example 8 (Preparation of granules)
[0044] Weigh the 7-day amount of raw medicine in proportion, add 10 times and 8 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of raw medicine per milliliter; add 3 times the amount of ethanol to the concentrated solution until the alcohol content reaches about 60%, refrigerate and stand for 24 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, concentrate the recovered liquid to a relative density of 1.25-1.30 (room temperature), add an appropriate amount of dextrin or starch, wet granulate, dry, make 500 grams of granules, and package them.
[0045] Example 9 (Preparation of granules)
[0046] Weigh 8 days' worth of the raw material medicine in proportion, add 11 times and 9 times the amount of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of the raw material medicine per milliliter; add 4 times the amount of ethanol to the concentrate, with an alcohol content of 60%, refrigerate and stand for 26 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, concentrate the recovered liquid to a relative density of 1.25-1.30 (room temperature), add an appropriate amount of dextrin or starch, wet granulate, dry, and make 520 grams of granules, which are packaged.
[0047] Example 10 (Preparation of granules)
[0048] Weigh 6 days' worth of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 meshes, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct for two to three times, combine the filtrates, and concentrate the filtrates to 5 grams of crude drug per milliliter; adopt Chitosan decoction flocculation precipitation method, let stand for 22 hours, centrifuge and filter, mix, concentrate the mixed solution to a relative density of 1.25-1.30 (room temperature), add appropriate amount of dextrin or starch and β-cyclodextrin inclusion complex of volatile oil of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius, perform wet granulation or one-step granulation, dry at low temperature or in vacuum, prepare 480 grams of granules, and pack them.
[0049] Example 11 (Preparation of granules)
[0050] Weigh 7 days' worth of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 meshes, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct for two to three times, combine the filtrates, and concentrate the filtrates to 5 grams of crude drug per milliliter; adopt Chitosan decoction flocculation precipitation method, let stand for 24 hours, centrifuge and filter, mix, concentrate the mixed solution to a relative density of 1.25-1.30 (room temperature), add appropriate amount of dextrin or starch and β-cyclodextrin inclusion complex of volatile oil of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius, perform wet granulation or one-step granulation, dry at low temperature or in vacuum, prepare 500 grams of granules, and package them.
[0051] Example 12 (Preparation of granules)
[0052] Weigh 8 days' worth of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 meshes, extract volatile oil by steam distillation or supercritical extraction for later use; add 5-10 times amount of water to the residues of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius and the other raw materials weighed in proportion, decoct for two to three times, combine the filtrates, and concentrate the filtrates to 5 grams of crude drug per milliliter; adopt Chitosan decoction flocculation precipitation method, let stand for 26 hours, centrifuge and filter, mix, concentrate the mixed solution to a relative density of 1.25-1.30 (room temperature), add appropriate amount of dextrin or starch and β-cyclodextrin inclusion complex of volatile oil of Radix Rehmanniae, Salvia miltiorrhiza and Carthamus tinctorius, perform wet granulation or one-step granulation, dry at low temperature or in vacuum, prepare 520 grams of granules, and pack them.
[0053] The beneficial effects of the medicine of the present invention are further illustrated by test examples below. These tests are conducted using the Chinese medicine composition of the present invention (hereinafter also referred to as the Bushen Huoxue Recipe):
[0054] Experimental case (clinical study on the intervention of Bushen Huoxue prescription on atherosclerosis combined with hyperhomocysteinemia)
[0055] 1. Test subjects
[0056] This study selected patients who visited the geriatric outpatient clinic, ward, and atherosclerosis specialist clinic of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and the ward of Zhongren Geriatric Nursing Hospital in Jinshan District, Shanghai from January 1, 2022 to January 1, 2024. Participating cases must meet the Western medical diagnostic criteria for carotid atherosclerosis and hyperhomocysteinemia and the diagnostic criteria for kidney deficiency and blood stasis in traditional Chinese medicine. According to the random number table method, the cases were randomly divided into a combined Chinese and Western medicine group and a Western medicine group, and then followed up for 3 months.
[0057] 2. Experimental Design
[0058] According to the random number table method, this study randomly divided patients with kidney deficiency and blood stasis type carotid atherosclerosis combined with hyperhomocysteinemia into a Chinese and Western medicine group and a Western medicine group.
[0059] (1) Integrated Chinese and Western medicine group: Among the patients with kidney deficiency and blood stasis type CAS combined with Hhcy, the Chinese medicine compound Bushen Huoxue prescription and moderate-intensity statin (atorvastatin 10 mg, see treatment plan) were used for treatment, defined as the integrated Chinese and Western medicine group. The original treatment plan was maintained, including drug treatment for hypertension, diabetes, hyperuricemia, coronary heart disease, etc.
[0060] (2) Western medicine group: Among the patients with kidney deficiency and blood stasis type CAS combined with Hhcy, moderate-intensity statin therapy [19-20] (atorvastatin 10 mg) was used, defined as the Western medicine group. The original treatment plan was maintained, including drug treatment for hypertension, diabetes, hyperuricemia, coronary heart disease, etc.
[0061] 3. Treatment options
[0062] (1) Control group: According to the “Guidelines for Blood Lipid Management in China (2023)”
[19] , it is recommended that moderate-intensity statins (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, pitavastatin 1-4 mg, pravastatin 40 mg, simvastatin 20-40 mg, and Xuezhikang 1.2 g) be used as the initial drug treatment on the basis of lifestyle intervention. Therefore, this study used atorvastatin 10 mg QN lipid-lowering treatment on the basis of Western medicine anticoagulation.
[0063] (2) Treatment group: In addition to Western medicine anticoagulation and antiplatelet therapy, the patients also received moderate-intensity statin (atorvastatin 10 mg QN) and a traditional Chinese medicine compound prescription for invigorating the kidney and activating blood circulation (prescription composition: 15 g of Rehmannia glutinosa, 12 g of Cistanche deserticola, 15 g of Astragalus membranaceus, 6 g of Cyperus rotundus, 15 g of Salvia miltiorrhiza, 6 g of Carthamus tinctorius. This preparation is a traditional Chinese medicine decoction provided by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Dosage: 1 packet each time, once in the morning and once in the evening, taken warm after meals).
[0064] (3) The treatment course for both groups was 12 weeks, and the treatment group and the control group were prohibited from using other Chinese herbal preparations related to the treatment of this disease.
[0065] 4. Observation indicators:
[0066] (1) General information: name, age, gender, concomitant medication, allergy history, etc.
[0067] (2) Physical examination: Heart rate, blood pressure, respiration, and body weight were recorded before treatment, 4 weeks after treatment, and 12 weeks after treatment.
[0068] (3) Compliance observation: whether the patient can take the medication on time and in the prescribed dosage; whether the patient takes other medications on his own. The observation should be recorded every 4 weeks.
[0069] (4) Safety observation: ① Routine blood, urine, stool, liver and kidney function, blood sugar, creatine kinase, electrocardiogram, etc. were recorded before treatment, 4 weeks after treatment, and 12 weeks after treatment. ② Observe and record any adverse reactions after taking the medicine.
[0070] (5) Efficacy observation: Testing and recording were performed before treatment and 12 weeks after treatment.
[0071] Main efficacy indicators:
[0072] ① Vascular structure detection Carotid artery ultrasound examination of carotid cIMT and atherosclerotic plaque area. Testing instrument: Baisheng Charm 90 Expert Edition Ultrasound Diagnostic Instrument, pulse probe of 10-13MHZ, performed by the same skilled operator using the same instrument with concealed random grouping.
[0073] ② Serum homocysteine (Hcy) detection instrument: fully automatic biochemical detector (model: 7170, HITACHI company), completed by the laboratory department of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine.
[0074] Secondary efficacy indicators:
[0075] ① Blood lipid metabolism detection instrument: biochemical detector, model 7170, Hitachi. Completed by the laboratory department of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine.
[0076] ② TCM syndrome score was scored and recorded according to the TCM syndrome score table in accordance with the Guiding Principles for Clinical Research of New Chinese Medicines. The main symptoms were divided into four levels: none, mild, moderate, and severe, with scores of 0, 2, 4, and 6 points respectively; the secondary symptoms were divided into four levels: none, mild, moderate, and severe, with scores of 0, 1, 2, and 3 points respectively.
[0077] ③After completing 12 weeks of clinical observation, continue to take the medicine for 12 weeks for hard endpoint observation, and finally compare the average medication time, the incidence of endpoint events such as acute coronary syndrome and acute cerebrovascular accident between the two groups.
[0078] 5. Results
[0079] 5.1 General Information
[0080] A total of 72 cases were included in this study, including 36 cases in the integrated Chinese and Western medicine group and 36 cases in the Western medicine group. During the treatment, 1 subject dropped out in each group, and the loss to follow-up rate was 2.7%. Finally, a total of 70 subjects completed the 3-month observation follow-up and were included in the statistical analysis, with 35 cases in each group. The reason for the dropout of 1 subject in the integrated Chinese and Western medicine group was that he did not experience adverse reactions after taking the medicine on time for 1 month, but still refused the follow-up test and follow-up. The reason for the dropout of 1 subject in the Western medicine group was that he took Chinese patent medicine with the effect of promoting blood circulation and unblocking collaterals on his own 1 month after enrollment and refused the follow-up review.
[0081] The youngest patient was 64 years old and the oldest was 106 years old. There were 29 males (41.4%) and 41 females (58.6%). The average BMI was 23.38±0.99. Three patients (4.3%) had a history of smoking and three patients (4.3%) had a history of drinking. In terms of dietary habits, 16 patients (22.9%) chose a light diet, 26 patients (37.1%) chose a conventional diet, 24 patients (34.3%) chose a greasy diet, and 4 patients (5.7%) chose a salty diet. In terms of underlying diseases, there were 36 patients with hypertension (51.4%), 20 patients with diabetes (28.6%), 21 patients with hyperlipidemia (30.0%), 8 patients with hyperuricemia (11.4%), 48 patients with cerebrovascular disease (68.6%), and 54 patients with coronary heart disease (77.1%).
[0082] 5.2 Evaluation of main efficacy indicators
[0083] 5.2.1 Comparison of the maximum plaque area before and after treatment
[0084] Intra-group comparison: There was a significant difference in the maximum plaque area before and after treatment in the integrated Chinese and Western medicine group (Z=-5.159, P<0.01), indicating that the integrated Chinese and Western medicine treatment can effectively reduce the plaque area; there was no significant difference in the maximum plaque area before and after treatment in the Western medicine group (Z=-1.163, P=0.245>0.05), indicating that Western medicine alone was not effective in reducing the plaque area, see Table 1.
[0085] Comparison between groups: The median difference in the maximum plaque area before and after treatment in the combined Chinese and Western medicine group was -6.92 mm 2 The median difference in the maximum plaque area before and after treatment in the Western medicine group was 4.85 mm 2 . The independent sample Mann-Whitney U test showed that Z = -3.641, P < 0.01. This suggests that the combined treatment of traditional Chinese and Western medicine is more effective in reducing the maximum plaque area of the patient's carotid artery.
[0086] Table 1. Comparison of the maximum plaque area before and after treatment [M(P25, P75), mm 2 ]
[0087]
[0088] Note: *Intra-group comparison P<0.05, **Intra-group comparison P<0.01, ▲Inter-group comparison P<0.05, ▲▲Inter-group comparison P<0.01. The following charts are the same.
[0089] 5.2.2 Effectiveness of maximum plaque area regression after treatment
[0090] A total of 70 subjects were followed up for 3 months. The TCM and WM group included 35 cases, of which 2 were cured, 4 were markedly effective, 9 were effective, and 20 were ineffective, with a total effective rate of 42.9%; the WM group included 35 cases, of which no cure was found, only 1 was markedly effective, 3 were effective, and 31 were ineffective, with a total effective rate of 11.4%. The chi-square test results showed that there was a significant difference in the maximum plaque area regression efficiency between the TCM and WM group and the WM group (χ 2 =8.741, P=0.003<0.01), see Table 2. This shows that the combination of Chinese and Western medicine can more effectively reduce the area of carotid artery plaque in patients.
[0091] Table 2. Comparison of the total effective rate of maximum plaque area reduction among groups after treatment (cases)
[0092]
[0093] 5.2.3 Comparison of CIMT values before and after treatment
[0094] Intra-group comparison: Chinese and Western medicine combined group Z = -4.492, P < 0.01, Western medicine group Z = -4.399, P < 0.01. Combined with the specific values, it can be found that the CIMT value of the Chinese and Western medicine combined group was significantly lower than before, while the CIMT value of the Western medicine group was increased, see Table 3.
[0095] Comparison between groups: The median difference of CIMT before and after treatment in the integrated Chinese and Western medicine group was -0.10, and the median difference of CIMT before and after treatment in the Western medicine group was 0.10. After independent sample Mann-Whitney U test, Z = -6.599, P < 0.01, see Table 3. This indicates that the difference in the change of CIMT before and after between the two groups is significant, indicating that the integrated Chinese and Western medicine group is more effective than the Western medicine group in reducing CIMT values.
[0096] Table 3. Comparison of CIMT values before and after treatment [M (P25, P75)]
[0097]
[0098] 5.2.4 Effective conversion rate of soft spots after treatment
[0099] A total of 70 patients were followed up for 3 months, including 35 in the integrated Chinese and Western medicine group and 35 in the Western medicine group. Before treatment, there were 21 patients with soft plaques in the integrated Chinese and Western medicine group. After treatment, 2 plaques disappeared and 9 turned into mixed plaques or hard plaques. Before treatment, there were 14 patients with soft plaques in the Western medicine group. After treatment, 2 turned into mixed plaques or hard plaques. The chi-square test results showed that there was a statistically significant difference between the integrated Chinese and Western medicine group and the Western medicine group in the transformation of soft plaques (χ 2=5.221, P=0.022<0.05). This suggests that the combination of Chinese and Western medicine has a better effect on soft plaque transformation and can better stabilize plaques. See Table 4.
[0100] Table 4. Comparison of the effective rate of soft plaque transformation between groups after treatment (example, %)
[0101]
[0102] 5.2.5 Comparison of homocysteine index values before and after treatment
[0103] Intra-group comparison: Chinese and Western medicine combined group Z = -5.161, P < 0.01, Western medicine group Z = -5.160, P < 0.01. Combined with the specific values, it can be found that the homocysteine index value of the Chinese and Western medicine combined group was significantly lower than before, while the homocysteine index of the Western medicine group increased, see Table 5.
[0104] Comparison between groups: The median difference of homocysteine index before and after treatment in the integrated Chinese and Western medicine group was -1.70, and the median difference of homocysteine index before and after treatment in the Western medicine group was 2.20. After independent sample Mann-Whitney U test, Z = -7.196, P < 0.01, see Table 5. The difference in the change of homocysteine index before and after the two groups was significant, indicating that the integrated Chinese and Western medicine group was better than the Western medicine group in reducing homocysteine.
[0105] Table 5. Comparison of homocysteine index values before and after treatment [M (P25, P75), umol / L]
[0106]
[0107] 5.3 Evaluation of secondary efficacy indicators
[0108] 5.3.1 Comparison of blood lipid indexes before and after treatment
[0109] 5.3.1.1 Comparison of blood lipid TG indexes before and after treatment
[0110] Intra-group comparison: T=6.677, P<0.01 for the integrated Chinese and Western medicine group, T=4.780, P<0.01 for the Western medicine group, indicating that the blood lipid TG indicators of both groups were lower than before treatment, see Table 6.
[0111] Comparison between groups: The median difference of blood lipid TG before and after treatment in the integrated Chinese and Western medicine group was -0.09mmol / L, and the median difference of blood lipid TG before and after treatment in the Western medicine group was -0.09mmol / L. After independent sample Mann-Whitney U test, Z=-0.600, P=0.549>0.05, see Table 6. It is suggested that after 3 months of intervention, both simple Western medicine treatment and integrated Chinese and Western medicine treatment can effectively reduce blood lipid TG indicators, and there is no significant difference in the efficacy between the two.
[0112] Table 6. Comparison of blood lipid TG indexes before and after treatment [M (P25, P75), mmol / L]
[0113]
[0114] 5.3.1.2 Comparison of blood lipid TC index before and after treatment
[0115] Intra-group comparison: T=5.154, P<0.01 in the integrated Chinese and Western medicine group, T=4.544, P<0.01 in the Western medicine group, indicating that the blood lipid TC indexes in both groups were lower than before treatment, see Table 7.
[0116] Comparison between groups: The median difference of blood lipid TC before and after treatment in the integrated Chinese and Western medicine group was -0.27mmol / L, and the median difference of blood lipid TC before and after treatment in the Western medicine group was -0.21mmol / L. After independent sample Mann-Whitney U test, Z=-0.159, P=0.874>0.05, see Table 7. It is suggested that after 3 months of intervention, both simple Western medicine treatment and integrated Chinese and Western medicine treatment can effectively reduce blood lipid TC index, and there is no significant difference in the efficacy between the two.
[0117] Table 7. Comparison of blood lipid TC index before and after treatment [M (P25, P75), mmol / L]
[0118]
[0119] 5.3.1.3 Comparison of HDL-C index before and after treatment
[0120] Intra-group comparison: Paired sample T test before and after treatment showed that the T=-4.740, P<0.01, and the T=-7.973, P<0.01, in the Western medicine group, indicating that the HDL-C in both groups was higher than before treatment, see Table 8.
[0121] Comparison between groups: The median difference of HDL-C before and after treatment in the TCM and WM group was 0.11mmol / L, and the median difference of HDL-C before and after treatment in the WM group was 0.10mmol / L. After independent sample Mann-Whitney U test, Z=-0.523, P=0.601>0.05, see Table 8. It is suggested that after 3 months of intervention, both Western medicine treatment alone and TCM and WM treatment can effectively improve HDL-C index, and there is no significant difference in the efficacy between the two.
[0122] Table 8. Comparison of blood lipid HDL-C index before and after treatment [M (P25, P75), mmol / L]
[0123]
[0124] 5.3.1.4 Comparison of blood lipid LDL-C index before and after treatment
[0125] Intra-group comparison: T=5.475, P<0.01 for the integrated Chinese and Western medicine group, T=4.993, P<0.01 for the Western medicine group, indicating that the blood lipid LDL-C indexes of both groups were lower than before treatment, see Table 9.
[0126] Comparison between groups: The median difference of blood lipid LDL-C before and after treatment in the integrated Chinese and Western medicine group was -0.18mmol / L, and the median difference of blood lipid LDL-C before and after treatment in the Western medicine group was -0.13mmol / L. After independent sample Mann-Whitney U test, Z=-2.069, P=0.039<0.05, see Table 9. It is suggested that after 3 months of intervention, compared with Western medicine alone, the integrated Chinese and Western medicine treatment with the Chinese medicine compound Bushen Huoxue Fang has more benefits in lowering blood lipid LDL-C.
[0127] Table 9. Comparison of blood lipid LDL-C index before and after treatment (mmol / L) [M (P25, P75), mmol / L]
[0128]
[0129] 5.3.2 Effectiveness of reduction in TCM syndrome scores after treatment
[0130] Intra-group comparison: T=9.852, P<0.01 for the integrated Chinese and Western medicine group, T=5.770, P<0.01 for the Western medicine group, indicating that the TCM syndrome scores of both groups were lower than before treatment, see Table 10.
[0131] Comparison between groups: The median difference of TCM syndrome score before and after treatment in the combined Chinese and Western medicine group was -9.00, and the median difference of TCM syndrome score before and after treatment in the Western medicine group was -6.00. After independent sample Mann-Whitney U test, Z = -3.001, P = 0.003 < 0.01, see Table 10. It is suggested that both simple Western medicine treatment and combined Chinese and Western medicine treatment can reduce TCM syndrome score, but adding the Chinese medicine compound Bushen Huoxue recipe on the basis of Western medicine treatment can more effectively improve TCM syndrome score.
[0132] Table 10. TCM syndrome scores of the two groups before and after treatment
[0133]
[0134] There were 35 subjects in each group who were followed up for 3 months. In the combined Chinese and Western medicine group, there were 0 cured cases, 3 markedly effective cases, 21 effective cases, and 11 ineffective cases, with a total effective rate of 68.6%; in the Western medicine group, there were 0 cured cases, 1 markedly effective case, 10 effective cases, and 24 ineffective cases, with a total effective rate of 31.4%. The chi-square test results showed that there was a significant difference in the effective rate of reducing the TCM syndrome score between the combined Chinese and Western medicine group and the Western medicine group (χ 2=9.657, P=0.002<0.01), see Table 11. This shows that taking the Chinese medicine compound prescription of Bushen Huoxue on the basis of Western medicine treatment can more effectively improve the TCM syndrome score of patients.
[0135] Table 11. Comparison of the effective rate of TCM syndrome score reduction after treatment between groups (cases)
[0136]
[0137] 5.4 End point events
[0138] Follow-up was conducted 12 weeks after the end of treatment. There were 35 patients in the integrated Chinese and Western medicine group, no primary endpoint event occurred, and 1 secondary endpoint event occurred; there were 35 patients in the Western medicine group, 1 primary endpoint event occurred, and 11 secondary endpoint events occurred.
[0139] The chi-square test was used to compare the number of primary endpoint events, secondary endpoint events, and cumulative endpoint events between the two groups. The results showed that the number of primary endpoint events was: 2 =1.014, P=0.314>0.05, indicating that there was no significant statistical difference in the number of primary endpoint events between the two groups; the number of secondary endpoint events: χ 2 =10.057, P = 0.002 < 0.01, indicating that the number of secondary endpoint events in the integrated Chinese and Western medicine group was significantly lower than that in the Western medicine group; the cumulative number of endpoint events: χ 2 =11.430, P < 0.01, indicating that the cumulative number of endpoint events in the integrated Chinese and Western medicine group was significantly lower than that in the Western medicine group; this indicates that the addition of the Chinese herbal compound Bushen Huoxue recipe on the basis of Western medicine treatment can significantly reduce the incidence of secondary endpoint events and cumulative endpoint events, see Table 12.
[0140] Table 12. Comparison of the number of endpoint events between the two groups (cases, %)
[0141]
[0142] 5.5 Safety indicators
[0143] In this study, all patients did not experience allergic symptoms during treatment, and the test results of liver function, kidney function, and creatine kinase of all patients were within the normal range. Due to the low frequency of adverse events, there was no statistically significant difference.
Claims
1. A Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia, Its characteristics are: The Chinese medicine composition is a medicine prepared from the following raw materials in parts by weight: 12-15 parts of cooked rehmannia, 9-12 parts of cistanche deserticola, 12-15 parts of raw astragalus, 6-9 parts of cyperus rotundus, 15-30 parts of salvia miltiorrhiza and 6-9 parts of safflower.
2. The Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia according to claim 1, Its characteristics are: The weight proportions of the raw medicines are: 15 parts of Rehmannia glutinosa, 12 parts of Cistanche deserticola, 15 parts of Raw Astragalus, 6 parts of Cyperus rotundus, 15 parts of Salvia miltiorrhiza, and 6 parts of Carthamus tinctorius.
3. The Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia according to claim 1 or 2, Its characteristics are: The medicine is a mixture.
4. The Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia according to claim 1 or 2, Its characteristics are: The medicine is a granule.
5. A method for preparing the Chinese medicine composition according to claim 3, Its characteristics are: The steps include: Weigh each raw material medicine in proportion, add 9-11 times and 7-9 times of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of raw medicine per milliliter; add 2-4 times of ethanol to the concentrate, with an alcohol content of 60%, refrigerate and stand for 22-26 hours, filter, and recover ethanol from the filtrate until there is no alcohol taste; boil the recovered liquid, add appropriate amounts of sodium benzoate and ethyl paraben, filter and cool, add water to 480-520 ml, and fill while hot to obtain the product.
6. A method for preparing the Chinese medicine composition according to claim 3, Its characteristics are: The steps include: Weigh Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 mesh, extract volatile oil by steam distillation or supercritical extraction, and set aside; The residues of Rehmannia glutinosa, Salvia miltiorrhiza, and Carthamus tinctorius and the other raw materials weighed in proportion are respectively added with 5-10 times of water, decocted two to three times, the filtrates are combined, and the filtrates are concentrated to 5 grams of raw materials per milliliter; Adopt flocculation sedimentation method, let stand for 22-26 hours, centrifuge and filter at a centrifugal speed of 4980-5020 rpm, add volatile oils of Allium macrostemon, Acorus calamus and cinnamon twig to the filtrate, mix well, add appropriate amount of sodium benzoate and ethyl paraben, filter and cool, add water to 480-520 ml, and fill while hot.
7. A method for preparing the granules of the Chinese medicine composition according to claim 4, Its characteristics are: The steps include: Weigh each raw material medicine in proportion, add 9-11 times and 7-9 times of water respectively, decoct two to three times, combine the filtrates, and concentrate the filtrate to 5 grams of raw medicine per milliliter; add 2-4 times of ethanol to the concentrate, with an alcohol content of 60%, refrigerate and stand for 22-26 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, concentrate the recovered liquid to a relative density of 1.25-1.30, add an appropriate amount of dextrin or starch, wet granulate, dry, make granules, and package to obtain the product.
8. A method for preparing the granules of the Chinese medicine composition according to claim 4, Its characteristics are: The steps include: Weigh Rehmannia glutinosa, Salvia miltiorrhiza and Carthamus tinctorius in proportion, crush to 10-40 mesh, extract volatile oil by steam distillation or supercritical extraction, and set aside; The residues of Rehmannia glutinosa, Salvia miltiorrhiza, and Carthamus tinctorius and the other raw materials weighed in proportion are respectively added with 5-10 times of water, decocted two to three times, the filtrates are combined, and the filtrates are concentrated to 5 grams of raw materials per milliliter; The chitosan decoction flocculation precipitation method is adopted, the mixture is allowed to stand for 22-26 hours, and is centrifugally filtered. The mixed solution is concentrated to a relative density of 1.25-1.30, and an appropriate amount of dextrin or starch and β-cyclodextrin inclusion complex of Rehmannia glutinosa, Salvia miltiorrhiza, and safflower volatile oil are added. The mixture is granulated by a wet method or a one-step granulation method, and is dried at low temperature or in a vacuum to form granules, which are packaged to obtain the product.
9. Use of the Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating atherosclerosis combined with hyperhomocysteinemia.
Citation Information
Patent Citations
Medicine for treating cardiac and cerebral vascular disease
CN101099847A
Application of Shenkang injection in preparing drug for preventing and treating cardiovascular and cerebrovascular diseases
CN103099854A
Kidney-tonifying and turbidity-dissolving traditional Chinese medicine compound prescription and preparation method and anti-atherosclerosis application thereof
CN113521154A
Traditional chinese medicine composition, and preparation method therefor and application thereof
EP4112066A1
